2 news items
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
LSTA
20 May 24
of development of Lisata's product candidates. Actual results could differ materially from those contained in any forward-looking statement as a result
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
LSTA
23 Apr 24
and cost of development of Lisata's product candidates. Actual results could differ materially from those contained in any forward-looking statement
- Prev
- 1
- Next